641571-44-0

Usage

Properties

1. Chemical Structure: 2-Amino-6-chloro-9-[(2,3,5-tri-O-benzoyl-2-C-Methyl-β-D-ribofuranosyl)]-9H-purine is a nucleoside analogue.
2. Molecular Formula: Not provided, but it can be derived from the given structure.
3. Molecular Weight: Not provided, but it can be calculated based on the molecular formula.
4. Functional Groups: Contains an amino group (-NH2), a chlorine atom (Cl), and multiple benzoyl groups attached to the ribofuranosyl moiety.
5. Biological Activity: Studied for potential antiviral and antitumor properties.
6. Therapeutic Potential: Investigated as a potential therapeutic agent for various diseases.
7. Role in Drug Development: Valuable tool for understanding nucleoside biological activity and for developing drugs targeting purine metabolism.

Specific Content

1. Chemical Name: 2-Amino-6-chloro-9-[(2,3,5-tri-O-benzoyl-2-C-Methyl-β-D-ribofuranosyl)]-9H-purine.
2. Alternative Name: Also known as 2-Amino-6-chloro-9-(N-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine.
3. Derivative: Derived from purine.
4. Nucleoside Analog: Structurally related to nucleosides.
5. Chlorine Position: Chlorine atom at position 6 of the purine ring.
6. Ribofuranosyl Moiety: Ribofuranosyl group attached to the purine base, with multiple benzoyl groups at positions 2, 3, and 5.
7. Biological Studies: Investigated for antiviral and antitumor activities.
8. Potential Therapeutic Agent: Explored for therapeutic applications in various diseases.
9. Drug Development Tool: Used for understanding nucleoside biology and developing drugs targeting purine metabolism.

2-AMino-6-chloro-9-[(2,3,5-tri-O-benzoyl- 2-C-Methyl-β-D-ribofuranosyl)]-9H-purine's structure and properties make it a promising candidate for further research and potential drug development efforts.

Upstream product

• 10310-21-1 2-amino-6-chloropurine 
• 15397-15-6 1,2,3,5-tetra-O-benzoyl-2-C-methyl-β-D-ribofuranose 
• 30361-17-2 2-methyl-2,3,5-tribenzoyl-ribonolactol 
• 7392-74-7 (3R,4R,5R)-5-((benzoyloxy)methyl)-3-methyl-2-oxotetrahydrofuran-3,4-diyl dibenzoate 
• 98-88-4 benzoyl chloride 
• 492-30-8 2-C-methyl-D-ribono-1,4-lactone 
• 10310-21-1 2-Amino-6-chloropurin 

Downstream Products

• 640725-74-2 (2R,3R,4R,5R)-2-(2-amino-6-chloro-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 
• 915023-63-1 2-amino-6-(1-methylhydrazino)-9-(2',3',5'-tri-O-benzoyl-2'-methyl-β-D-ribofuranosyl)purine 
• 915023-64-2 2-amino-6-(1-methyl-2-methylsulfonylhydrazino)-9-(2',3',5'-tri-O-benzoyl-2'-methyl-β-D-ribofuranosyl)purine 
• 640725-73-1 (2R,3R,4R,5R)-2-(2,6-diamino-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 
• 374750-30-8 2'-C-methylguanosine 
• 1234492-49-9 (2R,3R,4R,5R)-2-(2-amino-6-(benzylamino)-9H-purin-9-yl)-5-(benzoyloxymethyl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate 
• 714249-80-6 (2R,3R,4R,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 
• 1234492-50-2 (2R,3R,4R,5R)-2-(2-amino-6-(phenethylamino)-9H-purin-9-yl)-5-(benzoyloxymethyl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate 
• 1234491-47-4 (2R,3R,4R,5R)-2-(2-amino-6-(benzylamino)-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 
• 1234490-83-5 INX-08189 
• 1234491-48-5 2,2-dimethylpropyl (2S)-2-((((2R,3R,4R,5R)-5-(2-amino-6-benzylamino-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)propionate 
• 1234491-37-2 (2S)-benzyl 2-((((2R,3R,4R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalene-1-yloxy)phosphorylamino)propanoate 
• 1234491-38-3 (2S)-2,4-difluorobenzyl 2-((((2R,3R,4R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalene-1-yloxy)phosphorylamino)propanoate 

Relevant academic research and scientific papers

BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E

The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.

Intracellular metabolism and potential cardiotoxicity of a β-D-2’-C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication

β-D-2’-C-Methyl-2,6-diaminopurine ribonucleoside (2’-C-Me-DAPN) phosphoramidate prodrug (DAPN-PD) is a selective hepatitis C virus inhibitor that is metabolized intracellularly into two active metabolites: 2’-C-Methyl-DAPN triphosphate (2’-C-Me-DAPN-TP) a

2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT

The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.

Synthesis and Evaluation of 2,6-Modified Purine 2′-C-Methyl Ribonucleosides as Inhibitors of HCV Replication

A variety of 2,6-modified purine 2′-C-methylribonucleosides and their phosphoramidate prodrugs were synthesized and evaluated for inhibition of HCV RNA replication in Huh-7 cells and for cytotoxicity in various cell lines. Cellular pharmacology and HCV polymerase incorporation studies on the most potent and selective compound are reported.

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in com

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS

The present invention is directed to a process for preparing diastereomerically enriched nucleoside phosphoramidates having the formula I: